J Rheumatol 2022 05 1;49(5):523-530. Epub 2022 Feb 1.
J. Widdifield, PhD, Sunnybrook Research Institute, ICES, Institute of Health Policy, Management, & Evaluation, University of Toronto, Toronto, Ontario, Canada.
Objective: To investigate coronavirus disease 2019 (COVID-19) hospitalization risk in patients with immune-mediated inflammatory diseases (IMIDs) compared with matched non-IMID comparators from the general population.
Methods: We conducted a population-based, matched cohort study using health administrative data from January to July 2020 in Ontario, Canada. Cohorts for each of the following IMIDs were assembled: rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis, systemic autoimmune rheumatic diseases (SARDs), multiple sclerosis (MS), iritis, inflammatory bowel disease, polymyalgia rheumatica, and vasculitis. Read More